Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis B or hepatitis C infection
10.1007/s40261-022-01163-5 · doi-reference
Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentre prospective cohort study
10.2340/00015555-2989 · doi-reference
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
10.1111/bjd.12461 · doi-reference
Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: A systematic review and meta-analysis
10.1007/s10238-022-00827-y · doi-reference
10.1007/s00403-024-03395-1
10.1007/s00403-024-03395-1 · doi-reference
The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV-positive individuals: A real-world cohort study
10.1111/jdv.19020 · doi-reference
Biologic treatment of 4 HIV-positive patients: A case series and literature review
10.1177/2475530320954279 · doi-reference
Recommendations for screening for hepatitis B infection prior to initiating anti-TNF-alpha inhibitors or other immunosuppressive agents in patients with psoriasis
10.1016/j.jaad.2013.08.049 · doi-reference
10.3390/v17010042
10.3390/v17010042 · doi-reference
Use of systemic therapies for treatment of psoriasis in people living with controlled HIV: Inference-based guidance from a multidisciplinary expert panel
10.1007/s13555-022-00722-0 · doi-reference
Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections
10.1016/j.jaad.2018.06.056 · doi-reference
Management of psoriasis patients with serious infectious diseases
10.1007/s12325-024-02873-2 · doi-reference
Managing psoriasis in patients with HBV or HCV infection: Practical considerations
10.1007/s40257-019-00457-3 · doi-reference
Hepatitis C guidance 2019 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection
10.1002/hep.31060 · doi-reference
10.1016/j.jhep.2020.08.018
10.1016/j.jhep.2020.08.018 · doi-reference
Risk for hepatitis B virus reactivation in patients with psoriasis treated with biological agents: A systematic review and meta-analysis
10.1007/s13555-022-00682-5 · doi-reference
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
10.1016/j.jaad.2017.01.037 · doi-reference
Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions
10.1053/j.gastro.2017.02.009 · doi-reference
AGA Clinical Practice Guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals
10.1053/j.gastro.2024.11.008 · doi-reference
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
10.1002/hep.29800 · doi-reference
Psoriasis in HIV infection: An update
10.1177/0956462419827673 · doi-reference
Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation
10.1016/j.jaad.2009.03.047 · doi-reference
HIV-associated psoriasis: Pathogenesis, clinical features, and management
10.1016/s1473-3099(10)70101-8 · doi-reference
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): Two phase 3, randomized, placebo-controlled and active-comparator-controlled trials
10.1016/s0140-6736(25)01576-4 · doi-reference
Oral icotrokinra for plaque psoriasis in adults and adolescents
10.1056/nejmoa2504187 · doi-reference
Icotrokinra: An oral interleukin-23 receptor antagonist peptide for the treatment of psoriasis
10.1007/s40257-026-01019-0 · doi-reference
EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris
10.1111/jdv.16915 · doi-reference
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
10.1016/j.jaad.2020.02.044 · doi-reference
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
10.1016/j.jaad.2018.11.057 · doi-reference
Psoriasis
10.1016/s0140-6736(14)61909-7 · doi-reference
